February 2022

breaking news

A new tool fight SARS-CoV-2: an ACE2-blocking antibody

In a new study, Du, et al., have identified a neutralising monoclonal antibody in humans, 87G7, against SARS-CoV-2 which has shown widespread neutralisation and immunisation efficacy against SARS-CoV-2 VOCs...

ChelekaFebruary 28, 2022

breaking news

Novel HIV-1 variant found in Netherlands: the implications

In recent study published in Science, Wymant, et al., reported the presence of a subtype-B variant of HIV-1 with high virulence that has been spreading through the Netherlands during recent…

ChelekaFebruary 24, 2022

breaking news

Understanding the immune system and COVID-19: New insights

Researchers today are still trying to understand how the immune system's natural killer (NK) cells identify SARS-CoV-2 infected cells. In a recent paper, Hammer, et al., have reported that NK…

ChelekaFebruary 23, 2022

breaking news

Ovarian cancer and immune evasion

In a new study published in Nature Communications, Launonen, et al., have identified and described the mechanism of how ovarian cancer hides from the body's immune system. These findings have…

ChelekaFebruary 18, 2022

breaking news

A new TB vaccine – is it cost-effective and efficient?

In a new study, Harris, et al., investigated the potential health impact and cost-effectiveness of the M72/AS01E vaccine in two high burden TB countries: India and South Africa

ChelekaFebruary 16, 2022

breaking news

More SARS-CoV-2 variants?

A recent paper by Foix, et al., has reported on the potential of existing strains of SARS-CoV-2, and future variants to escape the immune system's cytotoxic T cell response.

ChelekaFebruary 14, 2022

breaking news

HIV vaccine progress

In a recent paper, Ziyang, et al., have produced novel insights into and further developed an HIV vaccine through the use of a unique trimer in order to develop Tier-2…

ChelekaFebruary 10, 2022

breaking news

A nanoparticle based vaccine for SARS-CoV-2 neutralization and protection

In a recent study, researchers have demonstrated that the SARS-CoV-2 receptor-binding domain (RBD)-based, sortase A-conjugated nanoparticle (RBD-scNP) vaccine induces neutralizing antibodies (NAbs) in non-human primates (NHPs) against all eight variants of SARS-CoV-2.

ChelekaFebruary 7, 2022

breaking news

Predicting transplant rejection using proteoforms

In a recent study published in Science, Melani, et al., have reported on a several families of proteins in the body that may be used as a tool to predict…

ChelekaFebruary 6, 2022

breaking news

Epstein-Barr Virus found to trigger Multiple Sclerosis

For decades, researchers have suspected that patients infected with a common virus, Epstein-Barr (EVB), might be more likely to develop multiple sclerosis. Now, a team led by Harvard University researchers…

ChelekaFebruary 2, 2022

A new tool fight SARS-CoV-2: an ACE2-blocking antibody

Novel HIV-1 variant found in Netherlands: the implications

Understanding the immune system and COVID-19: New insights

Ovarian cancer and immune evasion

A new TB vaccine – is it cost-effective and efficient?

More SARS-CoV-2 variants?

HIV vaccine progress

A nanoparticle based vaccine for SARS-CoV-2 neutralization and protection

Predicting transplant rejection using proteoforms

Epstein-Barr Virus found to trigger Multiple Sclerosis

Advancing Global Online Immunology Education for 20 years

Join our Newsletter

Advancing Global Immunology Education